Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04253561
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : July 26, 2021
Roche Pharma AG
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 12, 2023
Estimated Study Completion Date : August 12, 2024